Archive for January 2nd, 2009

Business Wire - CombinatoRx Reports Positive Results for CRx-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial; Novel Combination Drug Candidate Demonstrates Clinical…

Friday, January 2nd, 2009

CAMBRIDGE, Mass. — CombinatoRx, Incorporated (NASDAQ: CRXX) today announced positive results of its single blind, phase 2, proof-of-concept clinical trial of CRx-170 in patients with asthma. CRx-170 is a novel synergistic combination drug candidate containing low dose budesonide and low dose nortriptyline. In this trial CRx-170 provided clinical benefit on FEV1 and demonstrated activity on i…